SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 321,542.60 |
| Enterprise Value ($M) | 349,810.60 |
| Book Value ($M) | 41,300.00 |
| Book Value / Share | 16.30 |
| Price / Book | 7.79 |
| NCAV ($M) | -36,872.00 |
| NCAV / Share | -14.56 |
| Price / NCAV | -8.72 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.00 |
| Return on Assets (ROA) | 0.00 |
| Return on Equity (ROE) | 0.01 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.00 |
| Current Ratio | 1.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 32,168.00 |
| Assets | 106,675.00 |
| Liabilities | 69,040.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 60,115.00 |
| Operating Income | 6,211.00 |
| Net Income | 365.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 13,006.00 |
| Cash from Investing | -14,083.00 |
| Cash from Financing | -4,810.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.66 | 7.73 | |
| 13G/A | BlackRock Inc. | 8.00 | -6.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 451,338 | 4,325,748 | 10.43 | |
| 551,940 | 4,869,125 | 11.34 | |
| 1,631,316 | 8,404,345 | 19.41 | |
| 490,511 | 5,992,700 | 8.19 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| HYAC – Haymaker Acquisition Corp. 4 | JNJ – Johnson & Johnson |
| LLY – Eli Lilly and Company | NUVB – Nuvation Bio Inc. |
| OGN – Organon & Co. |